From obesity through immunity to type 2 diabetes mellitus

International Journal of Diabetes in Developing Countries

Volumn 37, Issue 4, 2017, Pages 407-418

  Szablewski, Leszek ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Adaptive immunity; Adipose tissue; Diabetes mellitus; Gut microbiota; Innate immunity

Indexed keywords

EID: 85032572469     PISSN: 09733930     EISSN: 19983832     Source Type: Journal    
DOI: 10.1007/s13410-016-0531-4     Document Type: Review

References (166)

1. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383:69–82.
2. Zaccardi F, Webb DR, Yates T, Davies MJ. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. Postgrad Med J. 2016;92:63–9. doi:10.1136/postgradmedj-2015-133281.
3. Velloso LA, Eizirik DL, Cnop M. Type 2 diabetes mellitus – an autoimmune disease? Nat Rev Endocrinol. 2013;9:750–5.
4. Itariu BK, Stulnig TM. Autoimmune aspects of type 2 diabetes mellitus—a mini-review. Gastroenterology. 2014;60:189–96.
5. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care. 2003;26:510–3.
6. Yende S, van der Poll T, Lee MJ, Huang DT, Newman AB, Kong L, et al. The influence of pre-existing diabetes mellitus on the host immune response and outcome of pneumonia: analysis of two multicenter cohort studies. Thorax. 2011;65:870–7.
7. Horvath P, Oliver SR, Zaldivar Jr FP, Radom-Aizik S, Galassetti PR. Effects of intravenous glucose and lipids on innate immune cell activation in healthy, obese and type 2 diabetic subjects. Physol Rep. 2015;3,2:e12249.
8. Chng MHY, Alonso MN, Barnes SE, Nguyen KD, Engleman EG. Adaptive immunity and antigen-specific activation in obesity-associated insulin resistance. Mediat Inflam. 2015; doi:10.1155/2015/593075.
9. Lumeng CN, Delprosto JB, Westcott DJ, Saltiel AR. Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes. Diabetes. 2008;57:3239–46.
10. Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diab Res Clin Pract. 2014;105:141–50.
11. van Greevenbroek MMJ, Schalkwijk CG, Stehouwer CDA. Obesity-associated low-grade inflammation in type 2 diabetes mellitus: causes and consequences. Natl J Med. 2013;71:174–87.
12. Le Sommer S, Pesaresi M, Martin-Granadas C, Deligebovic M. Protein tyrosine phosphatase 1B (PTP1B) in the immune system. Inflam Cell Signal. 2015;2:e965. doi:10.14800/ics.965.
13. Mraz M, Haluzik M. The role of adipose tissue immune cells in obesity and low-grade inflammation. J Endocrinol. 2014;222:R113–R7.
14. Seijkens T, Kusters P, Chatzigeorgiu A, Chavakis T, Lutgens E. Immune cell crosstalk in obesity: a key role for costimulation. Diabetes. 2014;63:2751–60.
15. Viardot A, Lord RV, Samars K. The effect of weight loss and gastric banding on the innate and adaptive immune system in type 2 diabetes and prediabetes. J Clin Endocrinol Metab. 2010;95:2845–50.
16. Ndisang JF, Rastogi S, Vannacci A. Immune and inflammatory processes in obesity, insulin resistance, diabetes, and related cardiometabolic complications. J Immunol Res. 2014. doi:10.1155/2014/579560.
17. Al-Suhaimi E, Shehzad A. Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity. Eur J Med Res. 2013;18:12.
18. Nito N, Hosoda T, Chiaki K, Sato K. Change of cytokine balance in diet-induced obese mice. Metabolism. 2000;49:1295–300.
19. Loffreda S, Yang SQ, Lin HZ, Karp GL, Brengman ML, Klein AS, et al. Leptin regulates proinflammatory immune responses. FASEB J. 1998;12:57–65.
20. Murray PJ, Allen JE, Biswas S, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41:14–20.
21. Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3:23–35.
22. McNeils JC, Olefsky JM. Macrophages, immunity, and metabolic disease. Immunity. 2014;41:36–48.
23. Nieto-Vazquez I, Fernandez-Veledo S, Kramer DK, Vila-Bedmar R, Garcia-Guerra L, Lorenzo M. Insulin resistance associated to obesity: the link TNF-α. Arch Physiol Biochem. 2008;114:183–94.
24. Vanderford NL. Defining the regulation of IL-1β- and CHOP-mediated β-cell apoptosis. Islets. 2010;2:334–6.
25. Odegaard JL, Chawla A. Alternative macrophage activation and metabolism. Annu Rev Pathol. 2011;6:275–97.
26. Espinoza-Jeménez A, Peón AN, Terrazas LI. Alternatively activated macrophages in type 1 and 2 diabetes. Med Inflamm. 2012; doi:10.1155/2012/815953.
27. Bilan PJ, Samokhvalov V, Koshkina A, Schertzer JD, Samaan MC, Klip A. Direct and macrophage-mediated actions of fatty acids causing insulin resistance in muscle cells. Arch Physiol Biochem. 2009;115:176–90.
28. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860–7.
29. Arora P, Garcia-Bailo B, Dastani Z, Brenner D, Villegas A, Malik S, et al. Genetic polymorphisms of innate immunity-related inflammatory pathways and their association with factors related to type 2 diabetes. BMC Med Genet. 2011;12:95. doi:10.1186/1471-2350-12-95.
30. Xu H. Obesity and metabolic inflammation. Drug Disc Today: Disease Mech. 2013;10:e21–e5.
31. Huh JY, Park YJ, Ham M, Kim JB. Crosstalk between adipocytes and immune cells in adipose tissue inflammation and metabolic dysregulation in obesity. Mol Cells. 2014;37:365–71.
32. Donath MY, Dalmas E, Sauter NS, Böni-Schnetzler M. Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity. Cell Metabol. 2013;17:860–72.
33. Cildir G, Akincilar SC, Tergaonkar V. Chronic adipose tissue inflammation: all immune cells on the stage. Trends Mol Med. 2013;19:487–500.
34. Richardson VR, Smith KA, Carter AM. Adipose tissue inflammation: feeding the development of type 2 diabetes mellitus. Immunobiology. 2013;218:1497–504.
35. Shu CJ, Benoist C, Mathis D. The immune system’s involvement in obesity-driven type 2 diabetes. Sem Immunol. 2012;24:436–42.
36. Brooks-Worell B, Narla R, Palmer JP. Biomarkers and immune-modulating therapies for type 2 diabetes. Trends Immunol. 2012;11:546–53.
37. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante Jr AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112:1796–808.
38. Kintscher U, Harte M, Hess K, Foryst-Ludwig A, Klemenz M, Wabitsch M, et al. T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol. 2008;28:1304–10.
39. Monney L, Sabatos CA, Gaglia JL. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415:536–41.
40. Rempel JD, Packiasamy J, Dean HJ, McGavock J, Janko A, Collister M, et al. Preliminary analysis of immune activation in early onset type 2 diabetes. Int J Circum Health. 2013. doi:10.3402/ijch.v72i0.21190.
41. Creely SJ, McTernan PG, Kusminski CM, Fisher ff M, NF DS, Khanolkar M, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. 2007;292:E740–E7.
42. Cardan E, Hogan AE, Corrigan M, Gaotswe G, O’Connell J, Foley N, et al. The impact of childhood obesity on inflammation, innate immune frequency, and metabolic MicroRNA expression. J Clin Endocrinol Metab. 2014;99:E474–E8.
43. Shih Y-L, Ho K-T, Tsao C-H, Chang Y-H, Shiau M-Y, Huang C-N, et al. Role of cytokines in metabolism and type 2 diabetes mellitus. Int J Biomed Lab Sci. 2013;2:1–6.
44. Jin C, Henao-Mejia J, Flavell RA. Innate immune receptors: key regulators of metabolic disease progression. Cell Metabol. 2013;17:873–82.
45. Wieser V, Moschen AR, Tilg H. Inflammation, cytokines and insulin resistance: a clinical perspective. Arch Immunol Ther Exp. 2013;61:119–25.
46. Zhu M, Nikolajczyk BS. Immune cells link obesity-associated type 2 diabetes and peridontitis. J Dent Res. 2014;93:346–52.
47. Patel PS, Buras ED, Balasubramanyam A. The role of the immune system in obesity and insulin resistance. J Obes. 2013;2013:616193. doi:10.1155/2013/616193.
48. Medzhitov R, Janeway Jr CA. An ancient system of host defense. Curr Opin Immunol. 1998;10:12–5.
49. Muzio M, Polentarutti N, Bosisio D, Manoi Kumar PP, Mantovani P. Toll-like receptor family and signaling pathway. Biochem Soc Trans. 2000;28:563–6.
50. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med. 2012;18:363–74.
51. Bao Y, Mo J, Ruan L, Li G. Increased monocytic CD14 + HLADRlow/− myeloid-derived suppressor cells in obesity. Mol Med Rep. 2014:2322–8. doi:10.3892/mmr.2014.2927.
52. El-Hafez HA, El-Aziz SMA. Association between immune competence and metabolic parameters in obesity. Trend Med Res. 2012;7:53–61.
53. Dinarello CA, Donath MY, Mandrup-Poulsen T. Role of IL-1β in type 2 diabetes. Curr Opin Endocrinol Diab Obes. 2010;17:314–21.
54. Mandrup-Poulsen T, Bendtzen K, Nerup J, Dinarello C, Svenson M, Nielsen J. Affinity-purified human interleukin 1 is cytotoxic to isolated islet of Langerhans. Diabetologia. 1986;29:63–7.
55. Pickup J, Crook M. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 1998;41:1241–8.
56. Crook M. Type 2 diabetes mellitus: a disease of the innate immune system? An update Diab Med 2004;21:203–207
57. Schmidt MI, Duncan BB, Sharett AR, Lindberg G, Savage PJ, Offenbacher A, et al. Markers of inflammation and prediction of diabetes mellitus in adults (atherosclerosis risk in communities study). Lancet. 1999;353:1649–52.
58. Barzilay JL, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the cardiovascular health study. Diabetes. 2001;50:2384–9.
59. Lindsay RS, Krakoff J, Hanson RL, Bennett PH, Knowler WC. Gamma globulin levels predict type 2 diabetes in the Pima Indian population. Diabetes. 2001;50:1598–603.
60. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004;27:813–23.
61. Sell H, Habich C, Eckel J. Adaptative immunity in obesity and insulin resistance. Nat Rev Endocrinol. 2012;8:709–16.
62. Bandaru P, Rajkumar H, Nappanveettil G. The impact of obesity on immune response to infection and vaccine: an insight into plausible mechanisms. Endocrinol Metab Synd. 2013;2:1000113.
63. Farnsworth CW, Shehatou CT, Maynard R, Nishitani K, Kates SL, Zuscik MJ, et al. A humoral immune defect distinguishes the response to Staphylococcus aureus infection in mice with obesity and type 2 diabetes from that in mice with type 1 diabetes. Inf Immun. 2015;83:2264–74.
64. Hunsche C, Hernandez O, De la Fuente M. Impaired immune response in old mice suffering from obesity and premature immunosenescence in adulthood. J Gerontolog A Biol Sci Med Sci. 2016;71:983–91.
65. Winer S, Chan Y, Paltser G, Truong D, Tsui H, Bahrami J, et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med. 2009;15:921–9.
66. + effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med. 2009;15:914–20.
67. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11:98–107.
68. van Exel E, Gussekloo J, de Craen RG, Frolich M, Bootsma-Van Der WA, Westendorp RG. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-plus study. Diabetes. 2002;51:1088–92.
69. Ilan Y, Maron R, Tukpah AM, Maioli TU, Murugaiyan G, Yang K, et al. Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc Natl Acad Sci U S A. 2010;107:9765–70.
70. + regulatory T cells in type 2 diabetic nephropathy. J South Med Univ. 2009;29:137–9.
71. Eller K, Kirsch A, Wolf AM. Potential role of regulatory T cells in reversing obesity-linked insulin resistance and diabetic nephropathy. Diabetes. 2011;60:2954–62.
72. Ohmura K, Ishimori N, Ohmura Y, Tokuhara S, Nozawa A, Horii S, et al. Natural killer T cells are involved in adipose tissues inflammation and glucose intolerance in diet-induced obese mice. Arterioscl Thromb Vasc Biol. 2010;30:193–9.
73. Pantham P, Aye ILMH, Powell TL. Inflammation in maternal obesity and gestational diabetes mellitus. Placenta. 2015;36:709–15.
74. Wen Y, Gu SL, Reddy MA, Natarajan R, Nadler JL. Elevated glucose and diabetes promote interleukin-12 cytokine expression in mouse macrophages. Endocrinology. 2006;147:2518–25.
75. Ha H, Yu MR, Choi YJ, Kitamura M, Lee HB. Role of high glucose-induced nuclear factor-ĸB activation in monocytes chemoattractant protein-1 expression by mesangial cells. J Am Soc Nephrol. 2002;13:894–902.
76. Chen JS, Lee HS, Jin JS, Chen A, Lin SH, Ka SM, et al. Attenuation of mouse mesangial cell contractility by high glucose and mannitol: involvement of protein kinase C and focal adhesion kinase. J Biomed Sci. 2004;11:142–51.
77. Goh SY, Cooper ME. Clinical review: the role of advanced glycation end products in progression and complication of diabetes. J Clin Endocrinol Metab. 2008;93:1143–52.
78. Morohoshi M, Fujisawa K, Uchimura I, Numano F. Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro. Diabetes. 1996;45:954–9.
79. Winkler G, Salamon F, Harmos G. Elevated serum tumor necrosis factor-alpha concentrations and bioactivity in type 2 diabetics and patients with android type obesity. Diab Res Clin Pract. 1998;42:169–74.
80. Imani F, Horii Y, Suthanthiran M, Skolnik EY, Makita Z, Sharma V, et al. Advanced glycosylation endproduct-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon γ: role in tissue remodeling. J Exp Med. 1993;178:2165–72.
81. del Aguila LF, Claffey KP, Kirwan JP. TNF-alpha impairs insulin signaling and insulin stimulation and glucose uptake in C2C12 muscle cells. Am J Phys. 1999;276:E849–E55.
82. Qi C, Pekala PH. Tumor necrosis factor-alpha-induced insulin resistance in adipocytes. Proc Soc Exp Biol Med. 2000;223:128–35.
83. Luo B, Chan WFN, Lord SJ, Nanji SA, Rajotte RV, Shapiro AMJ, et al. Diabetes induces rapid suppression of adaptive immunity followed by homeostatic T-cell proliferation. Scand J Immunol. 2007;65:22–31.
84. Berrou J, Fougeray S, Venot M, Chardiny V, Gautier J-F, Dulphy N, et al. Natural killer cell function, an important target for infection and tumor protection, is impaired in type 2 diabetes. PLoS One. 2013;8:e62418.
85. Zhang K, Kaufman RJ. From endoplasmic reticulum stress to the inflammatory response. Nature. 2008;454:455–62.
86. Saleh MA. Study complement activity and humoral immune response in type 2 diabetes mellitus. Diyala Agricult Sci J. 2011;3:34–46.
87. Hatanaka E, Monteagudo PT, Marrococ MS, Campi A. Neutrophils and monocytes as potentially important sources of proinflammatory cytokines in diabetes. Clin Exp Immunol. 2006;146:443–7.
88. Andreasen AS, Pedersen-Skovsgaard T, Berg RMG, Svendsen KD, Feldt-Rasmussen B, Pedersen BK, et al. Type 2 diabetes mellitus is associated with impaired cytokine response and adhesion molecule expression in human endotoxemia. Int Care Med. 2010; doi:10.1007/s00134-010-1845-1.
89. Leser TD, Molbak L. Better living through microbial action: the benefits of the mammalian gastrointestinal microbiota on the host. Environ Microbiol. 2009;11:2194–206.
90. Allin KH, Nielsen T, Pedersen O. Gut microbiota in patients with type 2 diabetes mellitus. Eur J Endocrinol. 2015;172:R167–R77.
91. Tremaroli V, Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012;489:242–9.
92. Moreno-Indias I, Cardona F, Tinahones FJ, Queipo-Ortuño MI. Impact of the gut microbiota on the development of obesity and type 2 diabetes mellitus. Front Microbiol. 2014;5:1–10.
93. Purchiaroni F, Tortora A, Gabrielli M, Bertucci F, Gigante G, Janiro G, et al. The role of intestinal microbiota and the immune system. Eur Rev Med Pharmacol Sci. 2013;17:323–33.
94. Delgado S, Suárez A, Mayo B. Identification of dominant bacteria in feces and colonic mucosa from healthy Spanish adults by culturing and by 16S rDNA sequence analysis. Dig Dis Sci. 2006;51:744–51.
95. Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominiguez-Bello MG, Contreras M, et al. Human gut microbiome viewed across age and geography. Nature. 2012;486:222–7.
96. Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al. The gut microbiota as an environmental factor that regulates fat storage. PNAS. 2004;101:15718–23.
97. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444:1027–31.
98. Turnbaugh P, Ridaura V, Faith J, Rey F, Knight R, Gordon J. The effect of diet on the human gut microbiome: a metagenomics analysis in humanized gnotobiotic mice. Sci Trans Med. 2009;1:6–14.
99. Santacruz A, Manos A, Warnberg J, Marti A, Martin-Matillas M, Compoy C, et al. Interplay between weight loss and gut microbiota composition in overweight adolescent. Obesity (Silver Spring). 2009;17:1906–15.
100. Walker AW, Ince J, Duncan SH, Webster LM, Holtrop G, Ze X, et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME. 2011;5:220–30.
101. Wu Y, Ding Y, Tanaka Y, Zhang W. Risk factor contributing to type 2 diabetes and recent advances in the treatment and prevention. Int J Med Sci. 2014;11:1185–200.
102. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A. 2010;107:14691–6.
103. Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, Keilbaugh SA, Hamady M, Chen YY, et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology. 2009;137:1716–24.
104. Chen J, He X, Huang J. Diet effects in gut microbiome and obesity. J Food Sci. 2014;79:R442–R7.
105. Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature. 2009;461:1282–6.
106. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A. 2007;104:979–84.
107. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761–72.
108. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990;249:1431–3.
109. Festi D, Schiumerini R, Eusebi LH, Marasco G, Taddia M, Colecchia A. Gut microbiota and metabolic syndrome. World J Gastroenterol. 2014;20:16079–94.
110. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core guts microbiome in obese and lean twins. Nature. 2009;457:480–4.
111. de La Serre CB, Ellis CL, Lee J, Hartman AL, Rutledge JC, Raybould HE. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am J Physiol-Gastrointestinal Liver Physiol. 2010;299:G440–G8.
112. Guerts L, Neyrinck AM, Delzenne NM, Knauf C, Cani PD. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and intervention using prebiotics. Beneficial Microb. 2014;5:3–17.
113. Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. Trends in Endocrinol Metabol. 2007;18:27–37.
114. Tam J, Vemuri VK, Liu J, Batkai S, Mukhopadhyay B, Godlewski G, et al. Peripheral CB1 cannobinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest. 2010;120:2953–66.
115. Muccioli GG, Naslain D, Backhed F, Reigstad LS, Lambert DM, Delzenne NM, et al. The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol. 2010;6:392.
116. Dray C, Knauf C, Daviaud D, Waget A, Boucher J, Buleon M, et al. Apelin stimulates glucose utilization in normal and obese insulin-resistant mice. Cell Metabol. 2008;8:437–45.
117. Duparc T, Colom A, Cani PD, Massaby N, Rastrelli S, Drougard A, et al. Central apelin controls glucose homeostasis via a nitric oxide-dependent pathway in mice. Antioxid Redox Signal. 2011;15:1477–96.
118. Guerts L, Lazarevic V, Derrien M, Everard A, Van Roye M, Knauf C, et al. Altered gut microbiota and endocannabinoid system tone in obese and diabetic leptin-resistant mice: impact on apelin regulation in adipose tissue. Front Microbiol. 2011;2:149.
119. Larsen N, Vogensen FK, van der Berg FW, Nielsen DS, Andreasen SA, Pedersen BK, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 2010;5:e9085.
120. Wall R, Ross RP, Shanohan F, O’Mahony L, O’Mahony C, Coakley M, et al. Metabolic activity of the enteric microbiota influences the fatty acid composition of murine and porcine liver and adipose tissue. Am J Clin Nutr. 2009;89:1393–401.
121. Qin L, Li Y, Cai Z, Li S, Zhu Y, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55–60.
122. Karlsson FH, Tremaroli V, Nookaew I, Bergstram G, Behre CJ, Fagerberg B, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;5:829–51.
123. Caricilli AM, Saad MJ. The role of gut microbiota on insulin resistance. Nutrients. 2013;5:829–51.
124. Stachowicz N, Kirsztan A. The role of gut microbiota in the pathogenesis of obesity and diabetes. Post Hig Med Dośw. 2013;67:288–303.
125. Murri M, Leiva I, Gomez-Zumaquero JM, Tinahones FJ, Cardona F, Soriguer F, et al. Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study. BMC Med. 2013;11:46.
126. Schipper HS, Nuboer R, Prop S, van den Ham HJ, de Boer FK, Kesmir C, et al. Systemic inflammation in childhood obesity: circulating inflammatory mediators and activated CD14++ monocytes. Diabetologia. 2012;55:2800–10.
127. O’Rourke RW, Kay T, Scholz MH, Diggs B, Jobe BA, et al. Alterations in T-cell subset frequency in peripheral blood in obesity. Obes Surg. 2005;15:1463–8.
128. Carolan E, Hogan AE, Corrigan M, Gaotswe G, O’Connell J, Foley N, et al. The impact of childhood obesity on inflammation, innate immune cells frequency, and metabolic MicroRNA expression. J Clin Endocrinol Metab. 2014;99:E474–E8.
129. Poher A-L, Altirriba J, Veyrat-Durebex C, Rohner-Jeanrenaud F. Brown adipose tissue activity as a target for the treatment of obesity/insulin resistance. Front Physiol. 2015;6:Art 4. doi:10.3389/fphys.2015.0004.
130. Rutkowski JM, Stern JH, Scherer PE. The cell biology of fat expansion. J Cell Biol. 2015;5:501–12.
131. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signaling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7:85–96.
132. Stöckli J, Fazakerley DJ, James DE. GLUT4 exocytosis. J Cell Sci. 2011;124:4147–59.
133. Lizcano JM, Alessi DR. The insulin signaling pathway. Curr Biol. 2002;12:R236–R8.
134. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;4:473–81.
135. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296:1655–7.
136. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw GJ, et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking protein kinase Akt2 (PKBβ). Science. 2001;292:1728–31.
137. Blüher M, Michael MD, Peroni OD, Ueki K, Carter N, Kahn BB, et al. Adipose tissue selective receptor knockout protects against obesity and obesity-related glucose intolerance. Dev Cell. 2002;3:25–38.
138. Cariou B, Postic C, Boudou P, Burcelin R, Kahn CR, Girand J, et al. Cellular and molecular mechanisms of adipose tissue plasticity in muscle insulin receptor knockout mice. Endocrinology. 2004;145:1926–32.
139. Blüher M, Kahn BB, Kahn CR. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science. 2003;299:572–4.
140. Boucher J, Softic S, Ouamari AE, Krumpoch MT, Kleinridders A, Kulkarni RN, et al. Differential roles of insulin and IGF-1 receptors in adipose tissue development and function. Diabetes. 2016;65:2201–13.
141. Softic S, Boucher J, Solheim MH, Fujisaka S, Haering M-F, Homan EP, et al. Lipodystrophy due to adipose tissue specific insulin receptor knockout results in progressive NAFLD. Diabetes. 2016; doi:10.2337/db16-0213.
142. Guerra C, Navarro P, Valverde AM, Arribas M, Brüning J, Kozak LP, et al. Brown adipose tissue-specific insulin receptor knockout shows diabetic phenotype without insulin resistance. J Clin Invest. 2001;108:1205–13.
143. Kurlawalla-Martinez C, Stiles B, Wang Y, Devaskar SU, Kahn BB, Wu H. Insulin hypersensitivity and resistance to streptozotocin-induced diabetes in mice lacking PTEN in adipose tissue. Mol Cell Biol. 2005;25:2498–510.
144. Colomiere M, Permezel M, Lappas M. Diabetes and obesity during pregnancy alter insulin signalling and glucose transporter expression in maternal skeletal muscle and subcutaneous adipose tissue. J Mol Endocrinol. 2010;44:213–23.
145. Qlang G, Kong HW, Xu S, Pham HA, Parle SD, Burr AA, et al. Lipodystrophy and severe metabolic dysfunction in mice with adipose tissue-specific insulin receptor ablation. Mol Metab. 2016;5:480–90.
146. Mitrou P, Raptis SA, Dimitriadis G. Insulin action in morbid obesity: a focus on muscle and adipose tissue. Hormones. 2013;12:201–13.
147. Cheng Z, Tseng Y, White MF. Insulin signaling meets mitochondria in metabolism. Trends Endocrinol Metab. 2010;21:589–98.
148. Emanuelli B, Peraldi P, Filloux C, Chavey C, Freidinger K, Hilton DJ, et al. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem. 2001;276:47944–9.
149. Zick Y. Ser/Thr phosphorylation of IRS proteins: a molecular basis for insulin resistance. Sci STKE. 2005;2005:p4.
150. Cai D, Yuan M, Frantz DE, Melendez PA, Hansen L, Lee J, et al. Local and systemic insulin resistance from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005;11:183–90.
151. Kalupahana NS, Claycombe KJ, Moustain-Moussa N. (n-3) Fatty acids alleviate adipose tissue inflammation and insulin resistance: mechanistics insights. Adv Nutr. 2011;2:304–16.
152. Rask-Madsen C, Kahn CR. Tissue-specific insulin signaling, metabolic syndrome, and cardiovascular disease. Artherioscler Thromb Vasc Biol. 2012;32:2052–9.
153. Mauer J, Chaurasia B, Plum L, Quast T, Hampel B, Blüher M, et al. Myeloid cell-restricted insulin receptor deficiency protects against obesity-induced inflammation and systemic insulin resistance. PLoS Genet. 2010;6:e1e000938.
154. Shurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab. 2007;92:1023–33.
155. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79–83.
156. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930–5.
157. Rui L, Yuan M, Frantz D, Schoelson S, White ME. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem. 2002;277:42394–8.
158. Peraldi P, Spigelman B. TNF-alpha and insulin resistance: summary and future prospects. Moll Cell Biochem. 1998;182:169–75.
159. Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med. 1999;245:621–5.
160. Hotamisligil GS, Murray DL, Choy LN, Spigelman BM. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A. 1994;91:4854–8.
161. Makki K, Froguel P, Wolowczuk I. Adipose tissue in obesity-related inflammation and insulin resistance: cells cytokines, and chemokines. ISNR Inflammation. 2013; doi:10.1155/2013/139239.
162. Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem. 2003;278:13740–6.
163. Ueki K, Fruman DA, Yballe CM, Fasshauser M, Klein J, Asamo T, et al. Positive and negative roles of p85 alpha and p85 beta regulatory subunits of phosphoinositide 3-kinase in insulin signaling. J Biol Chem. 2003;278:48453–66.
164. Tharp WG, Gupta D, Smith J, Jones KP, Jones AM, Pratley RE. Effects of glucose and insulin on secretion of amyloid-β by human adipose tissue cells. Obesity. 2016;4:1471–9.
165. Tomazic M, Janez A, Sketelj A, Kocijanic A, Eckel J, Sharma PM. Comparison of alterations in insulin signaling pathway in adipocytes from type II diabetic pregnant women with gestational diabetes mellitus. Diabetologia. 2002;45:502–8.
166. Mahesan AM, Ogunyemi D, Kim E, Paul ABM, Chen Y-DI. Insulin resistance in pregnancy is correlated with decreased insulin receptor gene expression in omental adipose: insulin sensitivity and adipose tissue gene expression in normal pregnancy. J Diab Mell. 2016;6:100–11.